Free Trial
NASDAQ:CVAC

CureVac Q2 2024 Earnings Report

CureVac logo
$4.78 +0.34 (+7.66%)
As of 02:37 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CureVac EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.28
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

CureVac Revenue Results

Actual Revenue
$15.55 million
Expected Revenue
$10.07 million
Beat/Miss
Beat by +$5.48 million
YoY Revenue Growth
N/A

CureVac Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 15, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

CureVac's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

CureVac Earnings Headlines

Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
CureVac FY2025 EPS Forecast Increased by Leerink Partnrs
See More CureVac Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CureVac? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CureVac and other key companies, straight to your email.

About CureVac

CureVac (NASDAQ:CVAC) N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

View CureVac Profile

More Earnings Resources from MarketBeat